Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer

NCT ID: NCT05827523

Last Updated: 2025-01-31

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 520 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-05-31
• Study Completion Date: 2030-12-31

Brief Summary

Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)

Detailed Description

The goal of this phase III randomized controlled trial is to compare the clinical efficacy of HIPEC with cisplatin (trial arm) compared to no HIPEC (control arm) during interval cytoreductive surgery followed by neoadjuvant chemotherapy, in patients with stage III-IV primary epithelial ovarian cancer.

Conditions

Ovarian Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

HIPEC

Interval cytoreductive surgery with HIPEC

Group Type: EXPERIMENTAL

Cisplatin

Intervention Type: DRUG

Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery

No HIPEC

Interval cytoreductive surgery without HIPEC

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Cisplatin

Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Signed and written informed consent,

2. Patients ≥18, <80 years old,

3. Diagnosed with histologically confirmed FIGO stage III-IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer treated with three cycles of neoadjuvant chemotherapy,

4. Treated with interval complete cytoreduction, or cytoreduction with no more than 2.5 mm depth of residual disease,

5. A life expectancy > 3 months as clinically judged,

6. Adequate organ function for cytoreductive surgery and HIPEC,

7. Women who are medically unable to conceive or who are of childbearing potential, agree to follow contraceptive guidelines during treatment and,

8. Patients can also consent to the provision of clinical information for secondary use, such as future biomedical research. However, in the future, subjects can participate in the main trial even if they do not intend to participate in sharing clinical information.

Exclusion Criteria

1. Diagnosed with non-epithelial ovarian carcinoma or borderline ovarian tumor

2. Patients who have not undergone neoadjuvant chemotherapy,

3. Interval cytoreduction with more than 2.5 mm depth of residual disease,

4. A life expectancy ≤3 months as clinically judged,

5. History of previous malignancy within five years prior to inclusion, that affects ovarian cancer treatment results, with the exception of carcinoma in situ, radically excised basal cell or squamous cell cancer of the skin, or synchronal endometrial carcinoma FIGO IA G1/2,

6. Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML,

7. Patients with active central nervous system metastasis and carcinoma meningitis or patients who have been previously treated for brain metastases must be in a stable state in radiology,

8. Patients with antibacterial, antifungal, or antiviral infections requiring systemic treatment (administration of parenteral antibiotics),

9. Active tuberculosis that is not controlled within 1 month of treatment,

10. Patients diagnosed with a psychiatric disorder or substance abuse disorder that would interfere with your ability to cooperate with the trial,

11. Patients with any contraindications to the use of cisplatin (i.e., hypersensitivity to cisplatin),

12. Patients with a history of allogeneic tissue/solid organ transplantation or bone marrow transplantation or a history of double umbilical cord transplantation or,

13. History or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, or interfere with the patient's participation, in the opinion of the treating investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Center, Korea

OTHER_GOV

Sponsor Role: lead

Responsible Party

Myong Cheol Lim, MD, PhD

Principal Researcher

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Myong Cheol Lim, MD, Ph.D

Role: CONTACT

gynlim@gmail.com

+820319201760

Facility Contacts

Myong Cheol Lim, MD, PhD

Role: primary

gynlim@gmail.com

+820319201760

Ji Hyun Kim, MD

Role: backup

gynlittle@gmail.com

Other Identifiers

NCC2023-0100

Identifier Type: -

Identifier Source: org_study_id